Free tool
FAERS Monitor: Brinsupri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217673 or its brand name (Brinsupri, Brensocatib). Reports on generic versions are filed under their own applications.
Reports
2,819
Serious
972
34% of reports
Hospitalization
441
Death reported
106
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- therapy interrupted353
- cough300
- headache259
- dyspnoea204
- hospitalisation183
- product dose omission issue183
- pneumonia175
- rash174
- alopecia150
- dry skin146
- off label use146
- fatigue134
- adverse drug reaction127
- hypertension122
- productive cough109
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 19 |
| 2025 | 268 |
| 2026 | 2,520 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,340 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 353 | 37.0 | 33.6 | 12,321 |
| productive coughSignal | 109 | 17.1 | 14.2 | 1,633 |
| adverse drug reactionSignal | 127 | 10.6 | 8.9 | 1,093 |
| hospitalisationSignal | 183 | 8.9 | 7.7 | 1,282 |
| dry skinSignal | 146 | 8.2 | 7.0 | 916 |
| coughSignal | 300 | 8.0 | 7.2 | 1,850 |
| alopeciaSignal | 150 | 5.7 | 4.9 | 582 |
| product dose omission issueSignal | 183 | 4.6 | 4.0 | 527 |
| hypertensionSignal | 122 | 4.3 | 3.6 | 309 |
| pneumoniaSignal | 175 | 4.0 | 3.5 | 402 |
| headacheSignal | 259 | 3.1 | 2.7 | 373 |
| rashSignal | 174 | 3.0 | 2.6 | 231 |
| dyspnoeaSignal | 204 | 2.7 | 2.4 | 221 |
| fatigue | 134 | 1.3 | 1.1 | 8 |
| off label use | 146 | 1.2 | 1.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.